| Comprehensive Online Oncology Database | |
|
Marketed Drug Target Table
Note: Report links have been disabled for this sample screen.
| SUBSCRIBER SEARCH | ||||||||
|
|
REPORT FORMAT Marketed Drug Target Table Note: Report links have been disabled for this sample screen. |
|
|||||||||||||
| 1-949-830-0448 | info@newmedinc.com | ||||||||||||||
Your search found 4 records. Click on a developer link to see more information.
| Product Source | Designation | Target | Approved/Filed Indications |
|
Amgen Affiliate(s): · Japan Tobacco · Lonza Biologics (terminated 6/03) Current as of: Dec-6-2007 | Generic Name: Panitumumab Brand Name: Vectibix Other Designation: ABX-EGF (formerly known as clone E7.6.3) Panitumumab is a fully human IgG2 monoclonal antibody (MAb) targeting the epidermal growth factor receptor (EGFr). | Epidermal growth factor (EGF) receptor (EGFr, ErbB-1, ErbB1, HEr-1, HEr1) | • colorectal cancer expressing the epidermal growth factor receptor (EGFr), metastatic, refractory, third line • colorectal cancer, metastatic, refractory to fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens, third line, expressing EGFr with non-mutated K-ras |
|
GlaxoSmithKline Affiliate(s): · University of Florida Gainsville Current as of: Dec-2-2007 | Generic Name: Topotecan Brand Name: Hycamtin, Hycaptamine Other Designation: NSC-609699, SK&F-104864 Topotecan, a water-soluble camptothecin analog, is a topoisomerase I inhibitor. | Topoisomerase I | • ovarian cancer, metastatic, second or third line-IV • small cell lung cancer (sclc), refractory, second line treatment-IV • small cell lung cancer (sclc), relapsed, when retreatment with the first line regimen is not considered appropriate, IV • cervical cancer, Stage IVb recurrent or persistent not amenable to curative treatment with surgery and/or radiation therapy, in combination with cisplatin-IV • small cell lung cancer (sclc), relapsed-PO |
|
PharmaMar Affiliate(s): · Ortho Biotech Products · University of Illinois · Swedish Orphan International · Genesis Pharma Current as of: Dec-2-2007 | Generic Name: Trabectedin Brand Name: Yondelis Other Designation: Ecteinascidin 743, ET-743, NSC 648766 Trabectedin, a novel marine compound derived from the tunicate Ecteinascidia turbinata, is a cytotoxic alkaloid and a DNA minor groove, guanine-specific interacting agent that also targets topo I, inducing topo I-mediated protein-linked DNA breaks. | Topoisomerase I | • soft tissue sarcoma, refractory to standard treatments |
|
Genentech Affiliate(s): · ImmunoGen · Roche · Protein Design Labs · Lonza Group Current as of: Dec-6-2007 | Generic Name: Bevacizumab Brand Name: Avastin Other Designation: rhuMAb-VEGF • NSC-704865 Bevacizumab is a recombinant humanized MAb antagonist of VEGFA; angiogenesis inhibitor. | Vascular endothelial growth factor (VEGF, VEGF-A, VEGFA) | • colorectal cancer, advanced, metastatic, first line (combination) • colorectal cancer, relapsed, metastatic, second line • non-small cell lung cancer (nsclc), non-squamous, inoperable, locally advanced, recurrent or metastatic, in combination with carboplatin and paclitaxel chemotherapy, first line • breast cancer, chemotherapy naive, first line, locally recurrent or metastatic, in combination with taxane chemotherapy • non-small cell lung cancer (nsclc), non-squamous, inoperable, locally advanced, recurrent or metastatic, in combination with platinum-based chemotherapy, first line • renal cell carcinoma (RCC), metastatic, in combination with interferon (IFN) alpha, first line |
| HOME | NEW MEDICINE | SITE MAP |
NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE: 1-949-830-0448 FAX: 1-949-830-0887
INFO@NEWMEDINC.COM